Free Trial
Andy Chen

Andy Chen Analyst Performance

Senior Analyst at Wolfe Research

Andy Chen is a stock analyst at Wolfe Research in the medical sector, covering 12 publicly traded companies. Over the past year, Andy Chen has issued 13 stock ratings, including buy and hold recommendations. While full access to Andy Chen's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andy Chen's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 0 Years
Buy Recommendations
69.23% 9 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy69.2%9 ratings
Hold30.8%4 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Andy Chen at Wolfe Research, the majority (69.2%) have been Buy recommendations, followed by 30.8% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
12 companies

Andy Chen, an analyst at Wolfe Research, currently covers 12 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
100.0%

Andy Chen of Wolfe Research specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
9 companies
75.0%
MED - DRUGS
2 companies
16.7%
MED - GENERIC DRG
1 company
8.3%

Andy Chen's Ratings History at Wolfe Research

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8/4/2025Upgrade$401.80Peer Perform
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
8/4/2025Reiterated Rating$20.95Peer Perform
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
7/1/2025Initiated Coverage$94.58$170.00Outperform
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
6/17/2025Initiated Coverage$29.80$55.00Outperform
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
6/17/2025Initiated Coverage$41.14$49.00Outperform
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6/17/2025Initiated Coverage$20.94Peer Perform
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
5/19/2025Upgrade$37.62$61.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
4/21/2025Upgrade$7.23$21.00Outperform
89BIO stock logo
ETNB
89BIO
2/4/2025Initiated Coverage$9.29Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2/4/2025Initiated Coverage$16.66$25.00Outperform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2/4/2025Initiated Coverage$38.79Peer Perform
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2/4/2025Initiated Coverage$13.70$20.00Outperform
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
2/4/2025Initiated Coverage$36.54$49.00Outperform